Request Free Sample ×
ReportInfographic

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

US Chronic Idiopathic Constipation Market

ID: MRFR/Pharma/17380-HCR
100 Pages
Vikita Thakur
Last Updated: April 06, 2026

US Chronic Idiopathic Constipation Market Research Report By Diagnosis (Blood Tests, Sigmoidoscopy, Colonoscopy, Balloon Expulsion Test, Anorectal Manometry), By Treatment (Drugs) and By End User (Hospitals & Clinics, Diagnostic Centers) - Growth & Industry Forecast 2025 To 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

US Chronic Idiopathic Constipation Market Infographic
Purchase Options
Compare License
Summary Table of Contents Segmentation Download PDF
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
  2.   1.1 EXECUTIVE SUMMARY
  3.     1.1.1 Market Overview
  4.     1.1.2 Key Findings
  5.     1.1.3 Market Segmentation
  6.     1.1.4 Competitive Landscape
  7.     1.1.5 Challenges and Opportunities
  8.     1.1.6 Future Outlook
  9. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
  10.   2.1 MARKET INTRODUCTION
  11.     2.1.1 Definition
  12.     2.1.2 Scope of the study
  13.       2.1.2.1 Research Objective
  14.       2.1.2.2 Assumption
  15.       2.1.2.3 Limitations
  16.   2.2 RESEARCH METHODOLOGY
  17.     2.2.1 Overview
  18.     2.2.2 Data Mining
  19.     2.2.3 Secondary Research
  20.     2.2.4 Primary Research
  21.       2.2.4.1 Primary Interviews and Information Gathering Process
  22.       2.2.4.2 Breakdown of Primary Respondents
  23.     2.2.5 Forecasting Model
  24.     2.2.6 Market Size Estimation
  25.       2.2.6.1 Bottom-Up Approach
  26.       2.2.6.2 Top-Down Approach
  27.     2.2.7 Data Triangulation
  28.     2.2.8 Validation
  29. 3 SECTION III: QUALITATIVE ANALYSIS
  30.   3.1 MARKET DYNAMICS
  31.     3.1.1 Overview
  32.     3.1.2 Drivers
  33.     3.1.3 Restraints
  34.     3.1.4 Opportunities
  35.   3.2 MARKET FACTOR ANALYSIS
  36.     3.2.1 Value chain Analysis
  37.     3.2.2 Porter's Five Forces Analysis
  38.       3.2.2.1 Bargaining Power of Suppliers
  39.       3.2.2.2 Bargaining Power of Buyers
  40.       3.2.2.3 Threat of New Entrants
  41.       3.2.2.4 Threat of Substitutes
  42.       3.2.2.5 Intensity of Rivalry
  43.     3.2.3 COVID-19 Impact Analysis
  44.       3.2.3.1 Market Impact Analysis
  45.       3.2.3.2 Regional Impact
  46.       3.2.3.3 Opportunity and Threat Analysis
  47. 4 SECTION IV: QUANTITATIVE ANALYSIS
  48.   4.1 Security, Access Control and Robotics, BY Diagnosis (USD Million)
  49.     4.1.1 blood tests
  50.     4.1.2 sigmoidoscopy
  51.     4.1.3 colonoscopy
  52.     4.1.4 balloon expulsion test
  53.     4.1.5 anorectal manometry
  54.     4.1.6 colonic transit study
  55.     4.1.7 defecography
  56.     4.1.8 others
  57.   4.2 Security, Access Control and Robotics, BY Treatment (USD Million)
  58.     4.2.1 drugs
  59.     4.2.2 surgery
  60.     4.2.3 acid neutralizers
  61.     4.2.4 laxatives and antidiarrheal
  62.     4.2.5 antiemetics
  63.     4.2.6 antiulcer
  64.     4.2.7 lubiprostone (amitiza)
  65.     4.2.8 linaclotide (linzess)
  66.     4.2.9 misoprostol (Cytotec)
  67.     4.2.10 colchicine/probenecid (Col-Probenecid)
  68.     4.2.11 others
  69.     4.2.12 Onabotulinumtoxin A (Botox)
  70.   4.3 Security, Access Control and Robotics, BY End-User Industries (USD Million)
  71.     4.3.1 hospitals
  72.     4.3.2 gastroenterology clinics
  73.     4.3.3 diagnostic centers
  74.     4.3.4 others
  75. 5 SECTION V: COMPETITIVE ANALYSIS
  76.   5.1 Competitive Landscape
  77.     5.1.1 Overview
  78.     5.1.2 Competitive Analysis
  79.     5.1.3 Market share Analysis
  80.     5.1.4 Major Growth Strategy in the Security, Access Control and Robotics
  81.     5.1.5 Competitive Benchmarking
  82.     5.1.6 Leading Players in Terms of Number of Developments in the Security, Access Control and Robotics
  83.     5.1.7 Key developments and growth strategies
  84.       5.1.7.1 New Product Launch/Service Deployment
  85.       5.1.7.2 Merger & Acquisitions
  86.       5.1.7.3 Joint Ventures
  87.     5.1.8 Major Players Financial Matrix
  88.       5.1.8.1 Sales and Operating Income
  89.       5.1.8.2 Major Players R&D Expenditure. 2023
  90.   5.2 Company Profiles
  91.     5.2.1 AbbVie (US)
  92.       5.2.1.1 Financial Overview
  93.       5.2.1.2 Products Offered
  94.       5.2.1.3 Key Developments
  95.       5.2.1.4 SWOT Analysis
  96.       5.2.1.5 Key Strategies
  97.     5.2.2 Boehringer Ingelheim (DE)
  98.       5.2.2.1 Financial Overview
  99.       5.2.2.2 Products Offered
  100.       5.2.2.3 Key Developments
  101.       5.2.2.4 SWOT Analysis
  102.       5.2.2.5 Key Strategies
  103.     5.2.3 Ironwood Pharmaceuticals (US)
  104.       5.2.3.1 Financial Overview
  105.       5.2.3.2 Products Offered
  106.       5.2.3.3 Key Developments
  107.       5.2.3.4 SWOT Analysis
  108.       5.2.3.5 Key Strategies
  109.     5.2.4 Takeda Pharmaceutical (JP)
  110.       5.2.4.1 Financial Overview
  111.       5.2.4.2 Products Offered
  112.       5.2.4.3 Key Developments
  113.       5.2.4.4 SWOT Analysis
  114.       5.2.4.5 Key Strategies
  115.     5.2.5 AstraZeneca (GB)
  116.       5.2.5.1 Financial Overview
  117.       5.2.5.2 Products Offered
  118.       5.2.5.3 Key Developments
  119.       5.2.5.4 SWOT Analysis
  120.       5.2.5.5 Key Strategies
  121.     5.2.6 Sucampo Pharmaceuticals (US)
  122.       5.2.6.1 Financial Overview
  123.       5.2.6.2 Products Offered
  124.       5.2.6.3 Key Developments
  125.       5.2.6.4 SWOT Analysis
  126.       5.2.6.5 Key Strategies
  127.     5.2.7 Salix Pharmaceuticals (US)
  128.       5.2.7.1 Financial Overview
  129.       5.2.7.2 Products Offered
  130.       5.2.7.3 Key Developments
  131.       5.2.7.4 SWOT Analysis
  132.       5.2.7.5 Key Strategies
  133.     5.2.8 GSK (GB)
  134.       5.2.8.1 Financial Overview
  135.       5.2.8.2 Products Offered
  136.       5.2.8.3 Key Developments
  137.       5.2.8.4 SWOT Analysis
  138.       5.2.8.5 Key Strategies
  139.   5.3 Appendix
  140.     5.3.1 References
  141.     5.3.2 Related Reports
  142. 6 LIST OF FIGURES
  143.   6.1 MARKET SYNOPSIS
  144.   6.2 US MARKET ANALYSIS BY DIAGNOSIS
  145.   6.3 US MARKET ANALYSIS BY TREATMENT
  146.   6.4 US MARKET ANALYSIS BY END-USER INDUSTRIES
  147.   6.5 KEY BUYING CRITERIA OF SECURITY, ACCESS CONTROL AND ROBOTICS
  148.   6.6 RESEARCH PROCESS OF MRFR
  149.   6.7 DRO ANALYSIS OF SECURITY, ACCESS CONTROL AND ROBOTICS
  150.   6.8 DRIVERS IMPACT ANALYSIS: SECURITY, ACCESS CONTROL AND ROBOTICS
  151.   6.9 RESTRAINTS IMPACT ANALYSIS: SECURITY, ACCESS CONTROL AND ROBOTICS
  152.   6.10 SUPPLY / VALUE CHAIN: SECURITY, ACCESS CONTROL AND ROBOTICS
  153.   6.11 SECURITY, ACCESS CONTROL AND ROBOTICS, BY DIAGNOSIS, 2024 (% SHARE)
  154.   6.12 SECURITY, ACCESS CONTROL AND ROBOTICS, BY DIAGNOSIS, 2024 TO 2035 (USD Million)
  155.   6.13 SECURITY, ACCESS CONTROL AND ROBOTICS, BY TREATMENT, 2024 (% SHARE)
  156.   6.14 SECURITY, ACCESS CONTROL AND ROBOTICS, BY TREATMENT, 2024 TO 2035 (USD Million)
  157.   6.15 SECURITY, ACCESS CONTROL AND ROBOTICS, BY END-USER INDUSTRIES, 2024 (% SHARE)
  158.   6.16 SECURITY, ACCESS CONTROL AND ROBOTICS, BY END-USER INDUSTRIES, 2024 TO 2035 (USD Million)
  159.   6.17 BENCHMARKING OF MAJOR COMPETITORS
  160. 7 LIST OF TABLES
  161.   7.1 LIST OF ASSUMPTIONS
  162.     7.1.1
  163.   7.2 US MARKET SIZE ESTIMATES; FORECAST
  164.     7.2.1 BY DIAGNOSIS, 2025-2035 (USD Million)
  165.     7.2.2 BY TREATMENT, 2025-2035 (USD Million)
  166.     7.2.3 BY END-USER INDUSTRIES, 2025-2035 (USD Million)
  167.   7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  168.     7.3.1
  169.   7.4 ACQUISITION/PARTNERSHIP
  170.     7.4.1

US Security, Access Control and Robotics Market Segmentation

Security, Access Control and Robotics By Diagnosis (USD Million, 2025-2035)

  • blood tests
  • sigmoidoscopy
  • colonoscopy
  • balloon expulsion test
  • anorectal manometry
  • colonic transit study
  • defecography
  • others

Security, Access Control and Robotics By Treatment (USD Million, 2025-2035)

  • drugs
  • surgery
  • acid neutralizers
  • laxatives and antidiarrheal
  • antiemetics
  • antiulcer
  • lubiprostone (amitiza)
  • linaclotide (linzess)
  • misoprostol (Cytotec)
  • colchicine/probenecid (Col-Probenecid)
  • others
  • Onabotulinumtoxin A (Botox)

Security, Access Control and Robotics By End-User Industries (USD Million, 2025-2035)

  • hospitals
  • gastroenterology clinics
  • diagnostic centers
  • others

Related Reports

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories
Case Study Cover Image
Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization ✓ ✓ ✓
Direct Access to Analyst ✓ ✓ ✓
Deliverable Format ✓ ✓ ✓
Platform Access ✗ ✗ ✓
Discount on Next Purchase 10% 15% 15%
Printable Versions ✗ ✗ ✓